Contact us if you would like more information about IntegraGen and our efforts.
12 January 2021 IntegraGen announced today its unaudited business figures for the year 2020. 18 September 2020 IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020. Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and confirms (…) » 16 September 2020 This press release was prepared and distributed by OncoDNA S.A. in accordance with the provisions of Articles 231-27 1 ° and 2 ° and 231-28 of the general regulations of the Autorité des marchés financiers (the “AMF”). 01 September 2020 IntegraGen’s Combined General Assembly for 2020 will be held on September 17, 2020 at 2 p.m. at the company’s headquarters which is located at Génopole Campus 1,Genavenir 8, Porte 840, 5 rue Henri Desbruères – 91000 Evry, France 09 July 2020 Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…) » 09 July 2020 IntegraGen announced unaudited sales for the first half of 2020 were 4,706 k€, an increase of 13% compared to the first half of 2019 and 15% on a like-for-like basis taking into account the sale of the company’s diagnostic business at the start of 2020. The growth in sales (…) » 10 June 2020 We are excited to provide you with important information regarding the release of a new version (v3.0) of MERCURY™. This updated version of MERCURY has a number of changes and improvements designed to enhance data analysis capabilities and the user experience. MERCURY v3.0 has (…) » 13 April 2020 IntegraGen announces the company’s MERCURY™ cloud-based analytical software tool has achieved Conformité Européenne (CE) marking. This registration enhances the ability for IntegraGen sell MERCURY throughout the European Union (EU). MERCURY is utilized by researchers and clinicians to assist with the analysis of sequencing data derived from small (…) » 03 April 2020 +20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020. 31 March 2020 We have undertaken (…) » IntegraGen reports 2020 revenue of €9.0 million, an increase of +10%, and a cash position of €5.0 million as of December 31, 2020
IntegraGen Reports Results for 1st Half of 2020
COMMUNIQUE PROVIDING THE INFORMATION NOTE AND THE DOCUMENT “OTHER INFORMATION RELATING TO CHARACTERISTICS, IN PARTICULAR LEGAL, FINANCIAL AND ACCOUNTING” OF THE COMPANY ONCODNA S.A.
COMBINED GENERAL ASSEMBLY
Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN
IntegraGen reports sales of €4.7 million in the first half of 2020, up 13%, and cash position of €5.8 million
What’s new with MERCURY?
Our latest release: MERCURY™ v3.0
IntegraGen Achieves CE Mark for Its MERCURY™ Cloud-based Software Tool Which Supports Molecular Tumor Profiling for Cancer Patients
IntegraGen reports 2019 annual results
IntegraGen Update – Still open to meet your research needs
IntegraGen is following the French Government’s recommendations and precautionary measures for COVID-19. As an essential supplier of genomic research services, we are committed to meeting the needs of our customers while also making every effort to protect the health and well-being of our employees and their families.
